Biogen Idec Chief Counsel Resigns Amid Tysabri Withdrawal, Wrongful Discharge Suit
This article was originally published in The Pink Sheet Daily
Executive Summary
Thomas Bucknam’s resignation as chief counsel of Biogen Idec comes less than two weeks after the marketing suspension of Tysabri, and three weeks after a wrongful discharge suit is brought against the company. VP and Chief Corporate Counsel Anne Marie Cook will serve as acting general counsel.
You may also be interested in...
Tysabri Could Return In Fall; Marketing Suspended By Biogen Idec And Elan
One fatal, confirmed case of progressive multifocal leukoencephalopathy and one suspected case prompt withdrawal of multiple sclerosis product; risk/benefit ratio needs to be reestablished, companies say. Return to market would not be unprecedented, but Tysabri’s withdrawal sharpens focus on FDA's drug safety oversight.
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
Changes To The NHS: How Can Pharma Best Position Itself?
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.